Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$0.67 USD
+0.04 (5.91%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $0.67 0.00 (0.74%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MBRX 0.67 +0.04(5.91%)
Will MBRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MBRX
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy
MBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MBRX
12 Health Care Stocks Moving In Thursday's After-Market Session
Moleculin Biotech (MBRX) Secures European Patent Notice for Annamycin
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin | MBRX Stock News
Moleculin Biotech receives notice of intent to grant new European patent
Moleculin receives notice of intent to grant new European patent for Annamycin